Novavax
Novavax develops protein-based nanoparticle vaccines using its Matrix-M adjuvant technology platform.
424B3Nov 12Latest SEC filing
Nov 5Latest story
Novavax develops protein-based nanoparticle vaccines using its Matrix-M adjuvant technology platform.